ARVN
ARVINAS, INC.
$7.42
-4.13%
$499.4M
No data for this timeframe.
Vol
Market Cap$499.4M
Cap SizeSmall Cap
Analyst ConsensusBuy (62%)
Inst. Holders7 funds
Inst. Value$116.9M
Inst. Activity2 buys / 3 sells
Insider Activity1B / 11S
Insider Net $-$356.2K
Reddit Sentiment33° Cool
SEC Reports13
Press Releases3
Recent Activity
Jun 5, 2026
SEC
Arvinas announced a pipeline reprioritization, planning to complete the Phase 1 monotherapy dose escalation trial for AR
8-K — Impact 6/10
Jun 5, 2026
fda_pdufa
PDUFA: ARVN — vepdegestrant in estrogen receptor positive (ER+) HER2-negative ESR1-mutated advanced or metastatic breast cancer — 2026-06-05
FDA target action date 2026-06-05 for ARVN (ARVINAS, INC.). Drug: vepdegestrant. Indication: estroge
May 21, 2026
Insider
Teel Randy sold 2,209 shares
President and CEO @ $9.04 ($20.0K)
May 12, 2026
SEC
Arvinas reported Q1 2026 revenue of $15.6M, a 91.7% decline from $188.8M in Q1 2025, driven by the completion of large m
8-K — Impact 6/10
May 12, 2026
SEC
Arvinas and Pfizer entered into a license agreement with Rigel Pharmaceuticals for exclusive global rights to VEPPANU (v
8-K — Impact 7/10
May 11, 2026
Insider
Teel Randy sold 9,657 shares
President and CEO @ $9.94 ($96.0K)
May 11, 2026
Insider
Berkowitz Noah sold 11,108 shares
Chief Medical Officer @ $9.94 ($110.4K)
Inst.
TWO SIGMA INVESTMENTS, LP — NEW
992,463 shares ($11.8M)
Price Targets
$15.00
+102.2% upside
Strong Buy
Current $7.42
Low $6.00
Median $15.50
High $24.00
16 analysts
$6.00
$24.00
Analyst Ratings
6Strong Buy
10Buy
9Hold
1Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 3, 2026 | Stephens & Co. | REITERATE | Overweight → Overweight |
| May 13, 2026 | Barclays | MAINTAIN | Overweight → Overweight |
| May 13, 2026 | BTIG | MAINTAIN | Buy → Buy |
| May 4, 2026 | Citigroup | MAINTAIN | Buy → Buy |
| Mar 19, 2026 | Citigroup | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.33 ▲ +47.6% | $-1.04 — $1.26 | 61% YoY | 15 |
| Next Q | $-0.83 ▲ +13.4% | $-1.15 — $-0.09 | -72% YoY | 15 |
| Current FY | $-2.90 ▲ +16.4% | $-4.08 — $-1.83 | -154% YoY | 15 |
| Next FY | $-3.33 ▲ +5.5% | $-5.30 — $-1.89 | -15% YoY | 15 |
Latest Reports
BEARISH
8-K
6/10
Arvinas announced a pipeline reprioritization, planning to complete the Phase 1 monotherapy dose escalation trial for AR
Jun 5, 2026
MIXED
8-K
6/10
Arvinas reported Q1 2026 revenue of $15.6M, a 91.7% decline from $188.8M in Q1 2025, driven by the completion of large m
May 12, 2026
BULLISH
Press
8/10
Arvinas (ARVN) announced FDA approval of VEPPANU (vepdegestrant), the first-ever PROTAC therapy, for ER+/HER2- ESR1-muta
May 1, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $85.7M | — |
| TWO SIGMA INVESTMENTS, LP | $11.8M | NEW |
| MORGAN STANLEY | $9.6M | TRIM |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $6.5M | NEW |
| BANK OF AMERICA CORP | $1.8M | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 21, 2026 | Teel Randy | SELL | $20.0K |
| May 11, 2026 | Teel Randy | SELL | $96.0K |
| May 11, 2026 | Berkowitz Noah | SELL | $110.4K |
| May 11, 2026 | Cacace Angela | SELL | $96.0K |
| May 11, 2026 | Loomis David | SELL | $19.1K |
Reddit Sentiment
33°
Cool
Bearish
Neutral
Bullish
7 institutional holders with $116.9M total value (9,854,243 shares) as of 2025-Q4. Top holders: VANGUARD, TWO, MORGAN. Net selling activity: 3 institutions trimmed/exited vs 2 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 7,229,603 | $85.7M | 73.4% | — |
| 2 | TWO SIGMA INVESTMENTS, LP | 992,463 | $11.8M | 10.1% | NEW |
| 3 | MORGAN STANLEY | 810,072 | $9.6M | 8.2% | TRIM -51.3% |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 547,476 | $6.5M | 5.6% | NEW |
| 5 | BANK OF AMERICA CORP /DE/ | 154,309 | $1.8M | 1.6% | TRIM -39.3% |
| 6 | WELLS FARGO & COMPANY/MN | 101,516 | $1.2M | 1.0% | ADD +58.6% |
| 7 | FMR LLC | 18,804 | $223.0K | 0.2% | ADD +88.1% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| TWO SIGMA INVESTMENTS, LP | NEW | — | 992,463 | — | $11.8M | 2025-Q4 |
| MORGAN STANLEY | TRIM | 1,662,221 | 810,072 | -51.3% | $9.6M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 254,401 | 154,309 | -39.3% | $1.8M | 2025-Q4 |
| FMR LLC | ADD | 9,995 | 18,804 | +88.1% | $223.0K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 669,655 | 0 | -100.0% | $0.00 | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 1,214,355 | 669,655 | -44.9% | $5.7M | 2025-Q3 |
| UBS Group AG | TRIM | 1,021,653 | 400,136 | -60.8% | $3.4M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | TRIM | 424,795 | 254,401 | -40.1% | $2.2M | 2025-Q3 |
| NORGES BANK | EXIT | 105,401 | 0 | -100.0% | $0.00 | 2025-Q3 |
| MORGAN STANLEY | ADD | 847,946 | 1,583,729 | +86.8% | $11.7M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 132,300 | 1,214,355 | +817.9% | $8.9M | 2025-Q2 |
| UBS Group AG | DOUBLED | 475,309 | 1,021,653 | +114.9% | $7.5M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | TRIM | 619,380 | 424,795 | -31.4% | $3.1M | 2025-Q2 |
| NORGES BANK | NEW | — | 105,401 | — | $775.8K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | ADD | 50,993 | 80,879 | +58.6% | $595.3K | 2025-Q2 |
| FMR LLC | NEAR_EXIT | 496,488 | 8,832 | -98.2% | $65.0K | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 128,247 | 0 | -100.0% | $0.00 | 2025-Q2 |
| CITADEL ADVISORS LLC | ADD | 3,148,068 | 4,223,946 | +34.2% | $29.7M | 2025-Q1 |
| FMR LLC | TRIM | 1,558,827 | 496,488 | -68.1% | $3.5M | 2025-Q1 |
| UBS Group AG | NEAR_EXIT | 2,038,459 | 475,309 | -76.7% | $3.3M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 68,900 | 132,300 | +92.0% | $928.7K | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 397,502 | 128,247 | -67.7% | $900.3K | 2025-Q1 |
| NORGES BANK | EXIT | 1,243,868 | 0 | -100.0% | $0.00 | 2025-Q1 |
| UBS Group AG | DOUBLED | 471,578 | 2,038,459 | +332.3% | $39.1M | 2024-Q4 |
| MORGAN STANLEY | ADD | 522,593 | 1,000,181 | +91.4% | $19.2M | 2024-Q4 |
7 unique insiders with 12 transactions. Net insider value: -$356.2K ($268.1K bought, $624.3K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 21, 2026 | Teel Randy | President and CEO | SELL | 2,209 | $9.04 | $20.0K |
| May 11, 2026 | Teel Randy | President and CEO | SELL | 9,657 | $9.94 | $96.0K |
| May 11, 2026 | Berkowitz Noah | Chief Medical Officer | SELL | 11,108 | $9.94 | $110.4K |
| May 11, 2026 | Cacace Angela M | Chief Scientific Officer | SELL | 9,657 | $9.94 | $96.0K |
| May 11, 2026 | Loomis David K | VP, Chief Accounting Officer | SELL | 1,919 | $9.94 | $19.1K |
| May 11, 2026 | Saik Andrew | Chief Financial Officer | SELL | 11,139 | $9.94 | $110.7K |
| Mar 18, 2026 | Berkowitz Noah | Chief Medical Officer | SELL | 6,435 | $11.10 | $71.4K |
| Mar 6, 2026 | Morrison Briggs | Director | BUY | 20,000 | $13.40 | $268.1K |
| Feb 27, 2026 | Houston John G | Director | SELL | 4,688 | $13.24 | $62.1K |
| Feb 26, 2026 | Loomis David K | VP, Chief Accounting Officer | A | 18,504 | $0.00 | $0.00 |
| Feb 26, 2026 | Berkowitz Noah | Chief Medical Officer | A | 45,000 | $0.00 | $0.00 |
| Feb 26, 2026 | Berkowitz Noah | Chief Medical Officer | A | 67,000 | $0.00 | $0.00 |
| Feb 26, 2026 | Loomis David K | VP, Chief Accounting Officer | A | 12,420 | $0.00 | $0.00 |
| Feb 26, 2026 | Cacace Angela M | Chief Scientific Officer | A | 45,000 | $0.00 | $0.00 |
| Feb 26, 2026 | Cacace Angela M | Chief Scientific Officer | A | 67,000 | $0.00 | $0.00 |
| Feb 26, 2026 | Saik Andrew | Chief Financial Officer | A | 45,000 | $0.00 | $0.00 |
| Feb 26, 2026 | Saik Andrew | Chief Financial Officer | A | 67,000 | $0.00 | $0.00 |
| Feb 26, 2026 | Teel Randy | President and CEO | A | 147,791 | $0.00 | $0.00 |
| Feb 26, 2026 | Teel Randy | President and CEO | A | 218,691 | $0.00 | $0.00 |
| Feb 26, 2026 | Teel Randy | President and CEO | A | 147,179 | $0.00 | $0.00 |
| Feb 23, 2026 | Loomis David K | Chief Accounting Officer | SELL | 1,108 | $12.16 | $13.5K |
| Feb 23, 2026 | Cacace Angela M | Chief Scientific Officer | SELL | 1,038 | $12.16 | $12.6K |
| Feb 23, 2026 | Teel Randy | President and CEO | SELL | 1,038 | $12.16 | $12.6K |
13 SEC filing reports analyzed. Sentiment: 3 bullish, 4 bearish, 1 mixed, 5 neutral. Avg impact: 5.2/10.
BEARISH
8-K
6/10
Arvinas announced a pipeline reprioritization, planning to complete the Phase 1 monotherapy dose esc
Jun 5, 2026
MIXED
8-K
6/10
Arvinas reported Q1 2026 revenue of $15.6M, a 91.7% decline from $188.8M in Q1 2025, driven by the c
May 12, 2026
BULLISH
8-K
7/10
Arvinas and Pfizer entered into a license agreement with Rigel Pharmaceuticals for exclusive global
May 12, 2026
BEARISH
PRESS-RELEASE
8/10
Arvinas reported Q1 2026 revenue of $15.6M (down 91.7% YoY from $188.8M) and a GAAP EPS of -$0.90, s
May 12, 2026
NEUTRAL
144
2/10
Officer Andrew Saik filed Form 144 to sell 11,343 shares of Arvinas common stock (approx. $114,678)
May 8, 2026
NEUTRAL
144
2/10
Noah Berkowitz, an officer of Arvinas, filed a Form 144 to sell 11,312 shares (approx. $114K) on May
May 8, 2026
BEARISH
PRESS-RELEASE
7/10
Arvinas reported Q4 2025 EPS of -$1.10, a 14.7% miss vs consensus of -$0.96, with revenue of $17.2M
May 5, 2026
BULLISH
8-K
8/10
Arvinas announced FDA approval of VEPPANU (vepdegestrant) for ER+/HER2-, ESR1-mutated advanced breas
May 1, 2026
NEUTRAL
DEFA14A
3/10
Arvinas filed additional definitive proxy soliciting materials (DEFA14A) on April 29, 2026. The actu
Apr 29, 2026
BULLISH
8-K
7/10
Arvinas announced positive Phase 1 clinical trial data for ARV-102, showing greater than 50% degrada
Mar 18, 2026
NEUTRAL
CLUSTER
3/10
A director at Arvinas, Inc. purchased $268,070 worth of shares in an open-market transaction, markin
Mar 9, 2026
NEUTRAL
CLUSTER
3/10
An insider at Arvinas, Inc. (ARVN) sold 4,688 shares in an open-market transaction, generating proce
Mar 3, 2026
BEARISH
CLUSTER
5/10
Three top executives at Arvinas — including the CEO, Chief Scientific Officer, and Chief Accounting
Feb 26, 2026
BULLISH
8/10
Arvinas (ARVN) announced FDA approval of VEPPANU (vepdegestrant), the first-ever PROTAC therapy, for
May 1, 2026
BULLISH
8/10
Arvinas presented positive Phase 1 data for ARV-102, showing approximately 50% or greater reduction
Mar 18, 2026
NEUTRAL
5/10
Arvinas announced that Phase 1 clinical trial data for its investigational Parkinson’s disease drug
Mar 11, 2026
Current analyst consensus: Buy (62% buy). Based on 26 analysts: 6 strong buy, 10 buy, 9 hold, 1 sell, 0 strong sell.
Analyst Price Targets
$15.00 mean target
+102.2% upside
Strong Buy (2.22)
$6.00 Low
$24.00 High
| Metric | Value |
|---|---|
| Current Price | $7.42 |
| Target Low | $6.00 |
| Target Mean | $15.00 |
| Target Median | $15.50 |
| Target High | $24.00 |
| # Analysts | 16 |
| Recommendation | Strong Buy (2.22) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.33 | $-1.04 | $1.26 | 61.2% | +47.6% | 9↑ 3↓ | $0.1B | 156.4% | 15 |
| Next Q 2026-09-30 |
$-0.83 | $-1.15 | $-0.09 | -72.3% | +13.4% | 8↑ 4↓ | $0.0B | -38.1% | 15 |
| Current FY 2026-12-31 |
$-2.90 | $-4.08 | $-1.83 | -154.1% | +16.4% | 9↑ 3↓ | $0.1B | -53.4% | 15 |
| Next FY 2027-12-31 |
$-3.33 | $-5.30 | $-1.89 | -14.9% | +5.5% | 6↑ 5↓ | $0.1B | -39.1% | 15 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.326 | |
| 7d ago | $-0.326 | |
| 30d ago | $-0.622 | +0.296 |
| 60d ago | $-0.651 | +0.325 |
| 90d ago | $-0.616 | +0.290 |
7 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 3, 2026 | Stephens & Co. | REITERATE | Overweight | Overweight |
| May 13, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| May 13, 2026 | BTIG | MAINTAIN | Buy | Buy |
| May 4, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Mar 19, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Mar 19, 2026 | BTIG | MAINTAIN | Buy | Buy |
| Mar 5, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Feb 25, 2026 | Piper Sandler | REITERATE | Overweight | Overweight |
| Feb 25, 2026 | Evercore ISI Group | MAINTAIN | Outperform | Outperform |
| Feb 25, 2026 | Wedbush | MAINTAIN | Neutral | Neutral |
| Jan 6, 2026 | Citigroup | UPGRADE | Neutral | Buy |
| Dec 17, 2025 | Barclays | MAINTAIN | Overweight | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 10 | 9 | 1 | 0 | 62% | |
| May 1, 2026 | 6 | 10 | 9 | 1 | 0 | 62% | |
| Apr 1, 2026 | 6 | 10 | 9 | 1 | 0 | 62% | |
| Mar 1, 2026 | 6 | 10 | 9 | 1 | 0 | 62% | |
| Feb 1, 2026 | 6 | 10 | 9 | 1 | 0 | 62% | |
| Jan 1, 2026 | 5 | 10 | 10 | 1 | 0 | 58% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
33°
Cool
Bearish
Neutral
Bullish
2 mentions
0 bullish
2 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 1, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| May 1, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
Recent Reddit Threads
Jun 5, 2026
fda_pdufa
PDUFA: ARVN — vepdegestrant in estrogen receptor positive (ER+) HER2-negative ESR1-mutated advanced or metastatic breast cancer — 2026-06-05
FDA target action date 2026-06-05 for ARVN (ARVINAS, INC.). Drug: vepdegestrant. Indication: estrogen receptor positive (ER+) HER2-negative ESR1-mutat
Jun 4, 2026
other
Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease
<p>NEW HAVEN, Conn., June 04, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on
May 29, 2026
other
Arvinas to Present at Jefferies Global Healthcare Conference
<p>NEW HAVEN, Conn., May 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of d
May 18, 2026
other
Arvinas Employees Give Back During Company-wide Impact Day
<p align="left">NEW HAVEN, Conn., May 18, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to c
May 12, 2026
earnings
Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update
<p align="center"><em>– First-ever FDA approved PROTAC supports the further development and </em><em>potential of Arvinas’ pipeline –</em></p>
May 12, 2026
earnings_calendar
ARVN Q1 2026 Earnings Scheduled — 2026-05-12
May 5, 2026
earnings
Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026
<p>NEW HAVEN, Conn., May 05, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company working to create a new class of drugs b
May 1, 2026
fda
Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
<p align="center"><em>– VEPPANU</em>™<em> is the first-and-only FDA-approved PROTAC, a type of heterobifunctional protein degrader –</em></p>
May 1, 2026
short_volume
Short Volume: ARVN — 61.5% short (0.5M / 0.8M)
Short: 510,972 | Exempt: 1,805 | TRF Vol: 830,971 | Short Ratio: 61.5% | Off-exchange volume (dark pool + OTC)
May 1, 2026
FDA
VEPPANU
Original Approval — Type 1 - New Molecular Entity — TABLET
Apr 30, 2026
earnings_calendar
ARVN Q1 2026 Earnings Scheduled — 2026-04-30
Apr 29, 2026
earnings_calendar
ARVN Q1 2026 Earnings Scheduled — 2026-04-29
Apr 15, 2026
Clinical Trial
A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer
Phase Phase 2 — COMPLETED
Mar 18, 2026
fda
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days
<p align="center"><em>– ARV-102 reduced endolysosomal and neuroinflammatory biomarkers implicated in Parkinson’s disease and progressive supranuclear
Mar 11, 2026
fda
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
<p align="center"><em>– Company to highlight new safety, pharmacokinetic, and pharmacodynamic data from Phase 1 clinical trial of ARV-102 in participa
Feb 24, 2026
earnings_calendar
ARVN Q4 2025 Earnings Before Market Open — 2026-02-24